Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

1 Feb 2022

Abstract excerpt

BACKGROUND: Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement with or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Genetic factors in colorectal cancer
Share to Multiple and Secondary Primary Cancers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35110358
DOI: 10.1136/jitc-2021-004001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersPMID 35110358Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite InstabilitySemantic proximity Read ↗

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read ↗

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair DeficiencySemantic proximity Read ↗

Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.Semantic proximity Read ↗

The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancersSemantic proximity Read ↗

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.Semantic proximity Read ↗

Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough ChallengeSemantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacySemantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.